Latest news

• Immunology keeps Shire figures solid as Takeda takeover nears

  HAE, prucalopride (SHP555) for chronic idiopathic constipation, and calaspargase pegol (SHP663) for the treatment of acute lymphoblastic leukaemia (ALL).

• Mallinckrodt pays $1.2bn for Sucampo Pharma

  As 2017 drew to a close, Mallinckrodt signed a deal to buy Sucampo Pharma of the US - and its constipation drug Amitizia - for $1.2bn. ... Amitizia is the prize asset in the deal, with FDA approvals in hand for three indications - chronic idiopathic

• FDA approves Synergy's constipation drug Trulance

  Synergy Pharma is celebrating after the FDA approved Trulance, its drug for the treatment of chronic idiopathic constipation (CIC) in adults. ... There are around 42 million people in the US who suffer from constipation, according to the National

• AZ and Ironwood to file IBS drug linaclotide in China next year

  A phase III trial of linaclotide in IBS with constipation (IBS-C) - conducted in China - showed that the drug improved symptoms such as abdominal pain and discomfort, bloating and straining whilst ... Linaclotide is a guanylate cyclase‐C agonist that

• Lilly’s Efient and Sucampo's Amitiza win NICE backing

  NICE, which provides healthcare recommendations to the NHS, issued new guidance on the use of Sucampo Pharma Europe's Amitiza (lubiprostone) for adults with chronic idiopathic constipation and updated its view ... Chronic idiopathic constipation can be